Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%...

Related Keywords

Japan ,United States ,Japanese ,Dan Budwick ,Raymond Stevens ,David Dalessio ,Danielle Keatley ,Company Annual Report On Form ,Duke University ,Nasdaq ,Division Of Endocrinology ,Exchange Commission ,Structure Therapeutics Inc ,Company Phase ,Davidd Alessio ,Tolerability Results ,Treatment Emergent Adverse Events ,Obesity Cohort ,Mixed Model ,Month Toxicology ,Investor Relations ,Oral Metabolic ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Markets ,